Cargando…

Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment

The aim of this study was to evaluate the humoral response to the SARS-CoV-2 infection and vaccination in the NMOSD patients, treated with various immunosuppresants (ISs). Serum IgG against the complete sequence of the receptor binding domain of the spike protein was measured using ELISA SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Jovicevic, Vanja, Ivanovic, Jovana, Momcilovic, Nikola, Andabaka, Marko, Tamas, Olivera, Veselinovic, Nikola, Cujic, Danica, Gnjatovic, Marija, Mesaros, Sarlota, Pekmezovic, Tatjana, Drulovic, Jelena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986231/
https://www.ncbi.nlm.nih.gov/pubmed/35421782
http://dx.doi.org/10.1016/j.msard.2022.103794
_version_ 1784682503665090560
author Jovicevic, Vanja
Ivanovic, Jovana
Momcilovic, Nikola
Andabaka, Marko
Tamas, Olivera
Veselinovic, Nikola
Cujic, Danica
Gnjatovic, Marija
Mesaros, Sarlota
Pekmezovic, Tatjana
Drulovic, Jelena
author_facet Jovicevic, Vanja
Ivanovic, Jovana
Momcilovic, Nikola
Andabaka, Marko
Tamas, Olivera
Veselinovic, Nikola
Cujic, Danica
Gnjatovic, Marija
Mesaros, Sarlota
Pekmezovic, Tatjana
Drulovic, Jelena
author_sort Jovicevic, Vanja
collection PubMed
description The aim of this study was to evaluate the humoral response to the SARS-CoV-2 infection and vaccination in the NMOSD patients, treated with various immunosuppresants (ISs). Serum IgG against the complete sequence of the receptor binding domain of the spike protein was measured using ELISA SARS-CoV-2 IgG, INEP, Belgrade. Seroconversion occurred in 8/10 patients with COVID-19, and in 5/9 after vaccination. One out of four patients treated with inebilizumab seroconverted (after COVID-19); antibodies were not detected in any of the remaining 3 patients who were vaccinated. Antibodies developed after COVID-19 in 4/5 patients treated with azathioprine and all treated with mycophenolate-mofetil, and after vaccination, in 5/6 patients treated with these ISs. Post-vaccination humoral response was impaired in our NMOSD patients treated with B-cell depleting therapies; seroconversion occurred in almost all patients treated with conventional synthetic disease modifying ISs.
format Online
Article
Text
id pubmed-8986231
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-89862312022-04-07 Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment Jovicevic, Vanja Ivanovic, Jovana Momcilovic, Nikola Andabaka, Marko Tamas, Olivera Veselinovic, Nikola Cujic, Danica Gnjatovic, Marija Mesaros, Sarlota Pekmezovic, Tatjana Drulovic, Jelena Mult Scler Relat Disord Correspondence The aim of this study was to evaluate the humoral response to the SARS-CoV-2 infection and vaccination in the NMOSD patients, treated with various immunosuppresants (ISs). Serum IgG against the complete sequence of the receptor binding domain of the spike protein was measured using ELISA SARS-CoV-2 IgG, INEP, Belgrade. Seroconversion occurred in 8/10 patients with COVID-19, and in 5/9 after vaccination. One out of four patients treated with inebilizumab seroconverted (after COVID-19); antibodies were not detected in any of the remaining 3 patients who were vaccinated. Antibodies developed after COVID-19 in 4/5 patients treated with azathioprine and all treated with mycophenolate-mofetil, and after vaccination, in 5/6 patients treated with these ISs. Post-vaccination humoral response was impaired in our NMOSD patients treated with B-cell depleting therapies; seroconversion occurred in almost all patients treated with conventional synthetic disease modifying ISs. Elsevier B.V. 2022-06 2022-04-06 /pmc/articles/PMC8986231/ /pubmed/35421782 http://dx.doi.org/10.1016/j.msard.2022.103794 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Jovicevic, Vanja
Ivanovic, Jovana
Momcilovic, Nikola
Andabaka, Marko
Tamas, Olivera
Veselinovic, Nikola
Cujic, Danica
Gnjatovic, Marija
Mesaros, Sarlota
Pekmezovic, Tatjana
Drulovic, Jelena
Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment
title Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment
title_full Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment
title_fullStr Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment
title_full_unstemmed Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment
title_short Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment
title_sort humoral response to sars-cov-2 infection and vaccines against covid-19 in patients with neuromyelitis optica spectrum disorders: impact of immunosuppressive treatment
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986231/
https://www.ncbi.nlm.nih.gov/pubmed/35421782
http://dx.doi.org/10.1016/j.msard.2022.103794
work_keys_str_mv AT jovicevicvanja humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment
AT ivanovicjovana humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment
AT momcilovicnikola humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment
AT andabakamarko humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment
AT tamasolivera humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment
AT veselinovicnikola humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment
AT cujicdanica humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment
AT gnjatovicmarija humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment
AT mesarossarlota humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment
AT pekmezovictatjana humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment
AT drulovicjelena humoralresponsetosarscov2infectionandvaccinesagainstcovid19inpatientswithneuromyelitisopticaspectrumdisordersimpactofimmunosuppressivetreatment